N Engl J Med 2018 Oct 20
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.   

Related Questions

Have the results from IMpassion130 changed the standard of care?

Received neoadjuvant ddAC/T followed by adjuvant capecitabine for residual disease and found to have metastatic pulmonary nodules within months of sur...

PDL1 status pending; BRCA wild type

PD-L1 is low and she has residual neuropathy from neoadjuvant paclitaxel.

In patients with prior perioperative immunotherapy with early relapse, would re-introduction of immunotherapy be reasonable with high TMB?